Prussian Blue vs Potassium Iodide: A Procurement Decision Guide for National Radiological Stockpiles

In January 2023, the WHO updated its Critical Medicines List for radiological and nuclear emergencies. The updated guidance — published alongside the policy document National Stockpiles for Radiological and Nuclear Emergencies: Policy Advice (ISBN 978-92-4-006787-5) — names the medicines every country is expected to maintain.

Two of those medicines, Potassium Iodide (KI) and Prussian Blue (also known as ferric hexacyanoferrate), are routinely confused. They are not interchangeable. They are complementary. The threat each one neutralises does not overlap.

A national stockpile that holds only one of these two medicines is prepared for one half of the radiological threat landscape. The procurement officer's first decision is not "which one" — it is "how much of each, and on what timeline."

Potassium Iodide is a competitive thyroid blocker. The thyroid gland concentrates iodine through a transport protein called the sodium-iodide symporter. When a high dose of stable, non-radioactive iodine is administered before or shortly after exposure, the symporter saturates with stable iodine. Radioactive iodine — primarily I-131, but also I-129 and I-125 — has nowhere to bind, and is excreted in the urine before it can deposit in thyroid tissue.

The protective effect is dose-dependent and time-dependent. According to the WHO's Iodine Thyroid Blocking: Guidelines for Use in Planning and Responding to Radiological and Nuclear Emergencies (ISBN 978-92-4-155018-5, 2017) and the FDA Guidance: Potassium Iodide as a Thyroid Blocking Agent (2001), KI administered simultaneously with exposure blocks approximately 97 percent of thyroid uptake. Administered 12 hours before exposure, it blocks roughly 90 percent. Administered 24 hours before, it still blocks around 70 percent. Administered 4 hours after, the protective effect drops sharply, and after 8 hours, KI provides limited residual benefit.

KI is useless against any radionuclide that is not iodine. This is not a limitation of the dose or the formulation — it is a function of the mechanism. The thyroid does not concentrate cesium. KI does not chelate. It will not help a patient internally contaminated with Cs-137 from a dirty bomb, with thallium from an industrial source incident, or with any of the transuranic elements (plutonium, americium, curium) that decorporation agents like Ca-DTPA and Zn-DTPA address.

Prussian Blue is an insoluble crystalline ion-exchange compound. Once swallowed, it does not cross the intestinal barrier. It remains in the gastrointestinal lumen, where its lattice structure exchanges potassium ions for cesium and thallium ions in the gut contents. The trapped radionuclides are then carried out of the body in feces.

The clinical effect is significant. Per the CDC Radiation Emergency Medical Management (REMM) clinical page on Prussian Blue and the FDA-approved prescribing information (Initial U.S. Approval, 2003), Prussian Blue reduces the biological half-life of cesium-137 from approximately 110 days to approximately 30 days. Thallium half-life drops from around 8 days to approximately 3 days.

Two procurement implications follow. First, Prussian Blue's effective window is not measured in hours. Treatment can begin immediately after exposure, but it remains useful across days and weeks of internal contamination, because cesium recirculates through the enterohepatic system and Prussian Blue interrupts that recirculation. Second, the dose schedule is intensive. The standard adult regimen is 3 grams orally three times per day — 9 grams total per day — sustained until urinary excretion of cesium falls below action thresholds. Pediatric patients aged 2 to 12 receive 1 gram three times per day.

The amount of Prussian Blue required to treat a single contaminated adult is therefore an order of magnitude greater, by mass, than the amount of KI required to protect a single adult. Stockpile quantities cannot be set by patient count alone. They must be set by patient count multiplied by treatment duration.

The two medicines occupy different positions on the emergency timeline.

For a procurement officer, this distinction has practical consequences. KI must be pre-positioned close to populations at risk — typically within evacuation zones, schools, civil-defence depots, and forward defence units. Centralised storage at a single national depot defeats the purpose, because the medicine cannot reach the population in time. Prussian Blue can be held centrally, at hospital pharmacies and at strategic regional reserves, because there is time to mobilise it once an incident is identified. What matters is that the depth of supply matches the duration of the treatment course.

The WHO's 2017 guidance on iodine thyroid blocking sets out dosage tiers by age band. Procurement teams should be aware of all four — and should match supply to the demographic profile of the population at risk.

For Prussian Blue, the regulatory dosing splits between adult and paediatric:

• Adults and adolescents: 3 grams orally, three times per day
• Children aged 2 to 12 years: 1 gram orally, three times per day
• Children under 2 years: not formally approved; clinical decision left to treating physician based on contamination level

The procurement implication is that a paediatric tier is required for both medicines. KI tablets at 32 mg and 65 mg cannot be substituted by halving the 130 mg adult tablet — the dosing margin in young children is too tight. Stockpiles built only on the 130 mg adult strength leave the most vulnerable population unprotected.

Different incident types produce different radionuclide profiles. The right antidote mix follows the threat — and the Prussian Blue vs Potassium Iodide split shifts depending on what is dispersed.

A procurement officer building or auditing a radiological stockpile should be able to answer eight questions. Each question maps directly to a supply decision.

1. What population are we protecting, and what is its age distribution? Determines dose-tier mix.
2. What is the dominant threat scenario for our geography? Determines KI-to-PB ratio.
3. What pre-positioning network can we use for time-critical doses? Determines KI distribution architecture.
4. What is our shelf life and rotation policy? KI hermetically packaged tablets retain potency for 5 years and longer; Prussian Blue, stored at 25 degrees Celsius and protected from light, has a defined manufacturer shelf life — confirm with supplier dossier.
5. What is the regulatory approval pathway in our jurisdiction? KI is widely registered; Prussian Blue carries orphan-drug status in most markets, which can extend lead times — though the WHO Model List of Essential Medicines lists it as essential for every country to stockpile.
6. What is the supplier's quality dossier? cGMP, WHO-aligned manufacturing, batch validation, certificate of analysis.
7. What is the lead time from purchase order to delivery? Critical for both pre-event pre-positioning and post-event surge.
8. What is the cost of inaction? A single missed thyroid-protection window is irreversible. Procurement costs are a small fraction of post-event medical and political costs.

Both medicines on this comparison appear on the WHO Model List of Essential Medicines. Potassium Iodide has been listed for decades. Prussian Blue — as potassium ferric hexacyanoferrate — has been listed since 1989. Despite Prussian Blue's orphan-drug status, the WHO position is unambiguous: every country should maintain a stockpile of both medicines.

For institutional buyers in Africa, MENA, and Latin America — where domestic pharmaceutical manufacturing rarely covers radiological countermeasures and procurement leans heavily on imports — the priority is matching supply to international regulatory benchmarks. Golden Hour Pharma supplies all three pillars of the radiological decorporation stockpile: Potassium Iodide (in three WHO-aligned strengths), Potassium Iodate as a long-shelf-life thyroid-blocking alternative for tropical climates, and Prussian Blue (ferric hexacyanoferrate) for cesium and thallium decorporation. Quality is anchored to WHO-aligned cGMP manufacturing, with full batch validation, certificate of analysis, and dossier support. The full nuclear antidote range is documented for institutional buyers reviewing stockpile composition.

Procurement officers planning a stockpile review for fiscal year 2026 should document, at minimum: existing KI inventory by strength and expiry, existing Prussian Blue inventory by lot and expiry, target population coverage, distribution architecture for time-critical doses, and the regulatory pathway for any new supplier. Where any of those columns is incomplete, the stockpile is not yet ready for the threat scenario it is meant to address.

Are Potassium Iodide and Prussian Blue interchangeable?

No. Potassium Iodide blocks radioactive iodine uptake in the thyroid; Prussian Blue removes cesium and thallium from the body after contamination has occurred. The mechanisms, target radionuclides, and operational windows do not overlap. A national stockpile that holds only one is prepared for one half of the radiological threat landscape.

Which radiation antidote is needed for a dirty bomb (RDD)?

Prussian Blue. The most common payload in a radiological dispersal device is Cesium-137, and Prussian Blue accelerates its elimination from the body. Potassium Iodide plays no role in a dirty-bomb scenario unless the device also disperses radioactive iodine, which is uncommon.

What is the correct Potassium Iodide dose for children?

WHO 2017 guidance specifies 16 mg for neonates under 1 month, 32 mg for infants and children aged 1 month to 3 years, 65 mg for children aged 3 to 12 years, and 130 mg for adolescents over 12, adults, and pregnant or breastfeeding women. Halving a 130 mg adult tablet is not an acceptable substitute for paediatric strengths — the dosing margin in young children is too tight.

How is Prussian Blue dosed in adults?

The standard adult regimen is 3 grams orally three times per day — 9 grams total per day — sustained until urinary excretion of cesium falls below action thresholds. Children aged 2 to 12 years receive 1 gram three times per day. The regimen continues for as long as internal contamination persists; cesium recirculates through the enterohepatic system, and Prussian Blue interrupts that recirculation across days and weeks.

Does Prussian Blue work after a Chernobyl- or Fukushima-style reactor release?

Prussian Blue plays a secondary role in reactor accidents. The dominant early dose from a fission-product release is radioactive iodine, which Prussian Blue cannot block — Potassium Iodide is the front-line countermeasure for that scenario. Cesium-137 and Cs-134 from a reactor release matter for medium-term ground contamination, where Prussian Blue can support decorporation if internal contamination is confirmed.

How long does Potassium Iodide remain effective after exposure?

KI is most effective when administered before, or simultaneously with, exposure — blocking approximately 97 percent of thyroid uptake. The protective effect drops sharply after 4 hours, and after 8 hours KI provides limited residual benefit. This is why KI must be pre-positioned with the population at risk, not held centrally at a national depot.

Is Prussian Blue still considered an essential medicine despite its orphan-drug status?

Yes. Prussian Blue (as potassium ferric hexacyanoferrate) has been on the WHO Model List of Essential Medicines since 1989, and the WHO 2023 stockpile policy explicitly names it as a medicine every country should maintain in a national radiological reserve. Orphan-drug status reflects rare clinical use in normal times, not low importance in emergency stockpile design.

• Radiation Poisoning: Symptoms, Timeline, and Treatment — clinical-to-procurement bridge on Acute Radiation Syndrome and the medicines that change H-ARS outcomes.
• What Medicines Belong in a National Radiation Emergency Stockpile? A 2026 Procurement Guide — full WHO-aligned stockpile composition for ministries.

• World Health Organization. National Stockpiles for Radiological and Nuclear Emergencies: Policy Advice. 2023. ISBN 978-92-4-006787-5.
• World Health Organization. Iodine Thyroid Blocking: Guidelines for Use in Planning and Responding to Radiological and Nuclear Emergencies. 2017. ISBN 978-92-4-155018-5.
• World Health Organization. WHO updates Critical Medicines List for radiation and nuclear emergencies. 27 January 2023.
• U.S. Food and Drug Administration. Radiological and Nuclear Emergency Preparedness — medical countermeasure information.
• U.S. Food and Drug Administration. Guidance: Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies. 2001.
• U.S. Centers for Disease Control and Prevention. Radiation Emergency Medical Management (REMM): Potassium Iodide clinical page and Prussian Blue clinical page.
• International Atomic Energy Agency. Generic Procedures for Medical Response During a Nuclear or Radiological Emergency. 2024.
• World Health Organization. Model List of Essential Medicines — 23rd list, 2023 (entries for potassium iodide and potassium ferric hexacyanoferrate).